Human Her2 / ErbB2 (498-648) Protein

<strong>Human Her2 / ErbB2 (498-648) Protein</strong>_x000D_ <strong>Catalog number:</strong> B2014868_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 18.5_x000D_ <strong>Supplied as:</strong> Lyophilized_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Yun S, Lee S, Park JP, Choo J, Lee EK. Modification of phage display technique for improved screening of high-affinity binding peptides J Biotechnol. 2019 Jan 10;289:88-92._x000D_ 2: de Vries EGE, Rüschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, de Groot DJA, Castellano D, Erb G, Naab J, Donica M, Deurloo R, van der Heijden MS, Viale G. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma Cancer Med. 2023 Jun;12(11):12071-12083._x000D_ 3: Sarina N, Abeldenov S, Turgimbayeva A, Zhylkibayev A, Ramankulov Y, Khassenov B, Eskendirova S. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2 Hum Antibodies. 2018 Feb 5;26(2):103-111._x000D_ 4: Marino MA, Pinker K, Leithner D, Sung J, Avendano D, Morris EA, Jochelson M. Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results Mol Imaging Biol. 2020 Jun;22(3):780-787._x000D_ 5: Shukla ND, Chiang RS, Colevas AD. Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan J Natl Compr Canc Netw. 2022 Feb;20(2):102-104._x000D_ 6: de Goeij BE, Vink T, Ten Napel H, Breij EC, Satijn D, Wubbolts R, Miao D, Parren PW. Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63 Mol Cancer Ther. 2016 Nov;15(11):2688-2697._x000D_ 7: Glinka EM, Edelweiss EF, Sapozhnikov AM, Deyev SM. A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells Gene. 2006 Jan 17;366(1):97-103._x000D_ 8: Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab Cancer Res. 2013 Mar 1;73(5):1635-46._x000D_ 9: Olaleye O, Spanov B, Ford R, Govorukhina N, van de Merbel NC, Bischoff R. Enrichment and Liquid Chromatography-Mass Spectrometry Analysis of Trastuzumab and Pertuzumab Using Affimer Reagents Anal Chem. 2021 Oct 12;93(40):13597-13605._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/17466328">10: Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, Pecorari F, Ward CW, Joos TO, Plückthun A. A designed ankyrin repeat protein evolved to picomolar affinity to Her2 J Mol Biol. 2007 Jun 15;369(4):1015-28. </a>_x000D_ _x000D_ <strong>Products Related to Human Her2 / ErbB2 (498-648) Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>